Tagged with research

USA PJ Brooks PhD, program director in the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) in the USA, highlights the importance of going beyond one disease at a time in clinical trials, some of the roadblocks that still remain…

Spain Joan Puig de Dou, CEO of Kymos Pharma, a Spanish analytical CRO, shares his insights in the changing dynamics of the industry and explains how remaining independent in the face of industry consolidation is a strategic priority to leverage both quality and specialization for the company’s clients.   When[biosimilars] come…

France Professor Alexander Eggermont, general director of Gustave Roussy, gives insights into the transformation of the Hospital under his ten-year leadership mandate. He also explains the rationale behind creating Cancer Core Europe, a collaborative platform of Europe’s seven leading cancer institutes.   Our system brings between 3500 and 4000 patients into…

Korea The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced technologies to drive the nation’s economic growth as well as better care for patients at home and abroad.   For…

Spain Luis Serrano, president of the Centre for Genomic Regulation (CRG) in Spain, gives an update on the Centre’s recent history and outlines the need for greater understanding of science and research within the Spanish political class.   When we enter discussions with the different political parties, I feel things are…

Korea Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four years, the need to foster local CROs if the government is to truly embrace innovation, and the cultural differences in…

Korea Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also explains his decision to focus on manufacturing oligonucleotides, the potential in that market, and the challenges to the next objectives.…

China Kang Wei, managing director for the R&D-based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment, shares her priorities for RDPAC in the next few years, her members’ contribution to the Chinese healthcare environment and the national Healthy China 2030 strategy, as well as the importance…

Malaysia Click here to download the Healthcare & Life Sciences Review Malaysia 2018. After recent elections conducted in May 2018 saw Mahathir Mohamad returning as Prime Minister after 15 years to seal a historic victory, Malaysia is again back on its feet. Bolstered by well-established institutions, a fully-functional IP framework and strong…

France INCa – Institut National du Cancer (The National Cancer Institute)       The National Cancer Institute (INCa) is the state agency of health and scientific expertise in oncology in charge of coordinating actions to fight against cancer. Created by the public health law of August 9, 2004, it is placed…

Korea Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine. Dr Park also provides his assessment of Korea’s challenge in commercialising its academic research.   NOV not only supports research…

Spain Andreu Mas-Colell, former minister of finance for Catalonia and president of the Barcelona Institute of Science and Technology (BIST), discusses the mission and activities of the institution as a driver of multidisciplinary research in the region. Mas-Colell also describes the condition of innovation and technology in Catalonia, highlights the region’s…